Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial is conducted to determine the optimal dose of LD02GIFRO in improvement of gastrointestinal motility between each dose group by comparing the effectiveness and safety in patients undergoing colon resection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Experimental | 300mg/day |
|
| Group 2 | Experimental | 600mg/day |
|
| Group 3 | Experimental | 900mg/day |
|
| Placebo | Placebo Comparator | Control Group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LD02GIFRO | Drug | comparison of different dosages of drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement of gastrointestinal motility | Evaluation gastrointestinal function to the time of improvement gastrointestinal motility | in hospitalization (Maximized 14 days) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asan medical center | Seoul | 138-736 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided